Transarterial chemoembolization (TACE) combined with immunotherapy and anti-angiogenic agents in intermediate-stage hepatocellular carcinoma (CHANCE2202): a target trial emulation study.
Chen JJ, Jin ZC, Zhou JW, Ding R, Tie J, Xin YJ, Zhang L, Huang M, Zhu XL, Zhou GH, Ji F, Zhu KS, Shi HB, Wu YM, Zhang WH, Yang WZ, Ding WB, Chen JZ, Ji JS, Xu AB, Zhao W, Wang Q, Dai ZY, Zheng CS, Zhao JW, Liu RB, Wu JB, Cao GS, Xing WG, Duan XH, Shao HB, Zhong BY, Zhao Y, Zhu HD, Ren ZG, Teng GJ.
Chen JJ, et al. Among authors: wang q.
EClinicalMedicine. 2026 Feb 6;92:103766. doi: 10.1016/j.eclinm.2026.103766. eCollection 2026 Feb.
EClinicalMedicine. 2026.
PMID: 41705016
Free PMC article.